Novartis is delivering two million treatments of its pediatric antimalarial to Zambia as part of its collaboration with Malaria No More’s Power of One campaign.
The campaign, which launched to the public in September 2013, uses social, mobile, and e-commerce technologies, enabling the public to purchase treatments for children in Zambia. Donors are able to share information with their social networks and encourage friends to donate.
Zambia is the first beneficiary country of this campaign sponsored by Novartis. One million treatments of Coartem Dispersible have been funded through public donations and Novartis matched these with a further one million treatments. These antimalarials will reduce the disease burden in Zambia, which accounts for up to 40% of infant mortality in that country.
“Although the incidence of malaria has decreased, the disease still kills a child every minute in Africa,” said Joseph Jimenez, CEO of Novartis. “Our commitment to Power of One reflects our company’s long-term efforts to fight malaria and Novartis remains dedicated to controlling and ultimately eliminating this deadly disease.”
Power of One is a global digital fundraising campaign that enables people around the world to help end child deaths from malaria, a preventable and treatable disease. This fatal disease has been recognized by the World Health Organisation as a priority area of public health. This year’s World Health Day focuses on vector-borne diseases, of which malaria is the most deadly.
“One and a half million treatments are already on the ground in Zambia thanks to the Power of One campaign, with a further 500,000 anticipated in the coming weeks,” said Martin Edlund, CEO, Malaria No More. “Power of One is resonating with the general public, and their donations will help us ensure that children in Zambia will have access to the treatment they need.”